CAS NO: | 502887-71-0 |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
Cas No. | 502887-71-0 |
Canonical SMILES | O=C(NC1=CC=C(OC(F)F)C=C1)CSC2=NC(CCC)=CC(N2)=O |
分子式 | C16H17F2N3O3S |
分子量 | 369.39 |
溶解度 | DMSO: 125 mg/mL (338.40 mM) |
储存条件 | Store at -20°C |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | MMP-9-IN-1 is a specific matrix metalloproteinase-9 (MMP-9) inhibitor, which selectively target the hemopexin (PEX) domain of MMP-9, but not other MMPs[1]. MMP-9-IN-1 (compound 2; 100 μM; 14 hours) does not cause notable cytotoxicity[1].MMP-9-IN-1 (compound 2; 10 μM) significantly inhibits cell proliferation of HT-1080 and MDA-MB-435 cells[1]. Cell Cytotoxicity Assay[1] Cell Line: COS-1 monkey epithelial cell lines MMP-9-IN-1 (compound 2; 20 mg/kg; intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks) results in a profound delay in tumor growth in NCR-Nu mice bearing MDA-MB-435/GFP tumor[1]. MMP-9-IN-1 inhibits cancer cell metastasis in vivo[1]. Animal Model: 4-5 week-old female NCR-Nu mice bearing MDA-MB-435/GFP tumor[1] [1]. Dufour A, et al. Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. Cancer Res. 2011 Jul 15;71(14):4977-88. |